ClinicalTrials.gg
Status unknownNCT04490434Updated Jul 29, 2020

Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs

A Phase 1 interventional study of DWP14012 and Celecoxib in Healthy Male Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-29.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

drug-drug interaction between DWP14012 and three different kinds of NSAIDs

Read the detailed description

to evaluate the safety/tolerability and pharmacokinetic drug-drug interaction between DWP14012 and three different kinds of NSAIDs in healthy male volunteers

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult Caucasian or Japanese or Korean aged 19 to 50 (inclusive) years, at the time of screening.
  • Subjects weighing between 50 kg and 90 kg with between 18 and 27 kg/m2 (inclusive) at screening visit.

Exclusion criteria

Exclusion Criteria:

  • Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
  • Those who have gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple appendectomy and herniotomy)
  • Those whose plasma (SGOT) and ALT (SGPT) exceed 1.5 times to the in screening including additional examinations prior to randomization
  • Subjects who have participated and taken drug in any other clinical trial (including bioequivalence study) within six months prior to study drug administration
  • Subjects who have donated a unit of whole blood within two months or blood components within one month prior to study drug administration
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Cohort 1, A (DWP14012/Celecoxib)

    Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.

    Drug: DWP14012 · Drug: Celecoxib

  • Experimental
    Cohort 1, B (DWP14012/Celecoxib)

    Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.

    Drug: DWP14012 · Drug: Celecoxib

  • Experimental
    Cohort 2, C (DWP14012/Naproxen)

    Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.

    Drug: DWP14012 · Drug: Naproxen

  • Experimental
    Cohort 2, D (DWP14012/Naproxen)

    Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.

    Drug: DWP14012 · Drug: Naproxen

  • Experimental
    Cohort 3, E (DWP14012/Meloxicam)

    Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.

    Drug: DWP14012 · Drug: Meloxicam

  • Experimental
    Cohort 3, F (DWP14012/Meloxicam)

    Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.

    Drug: DWP14012 · Drug: Meloxicam

Interventions

06

What researchers measure

Primary outcomes

  1. Arm A, Cmax,ss of Celecoxib

    Maximum measured plasma concentration at steady-state

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  2. Arm A, AUCτ,ss of Celecoxib

    Area under the plasma concentration-time curve

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  3. Arm B, Cmax,ss of DWP14012

    Maximum measured plasma concentration at steady-state

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  4. Arm B, AUCτ,ss of DWP14012

    Area under the plasma concentration-time curve

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  5. Arm C, Cmax,ss of Naproxen

    Maximum measured plasma concentration at steady-state

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  6. Arm C, AUCτ,ss of Naproxen

    Area under the plasma concentration-time curve

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  7. Arm D, Cmax,ss of DWP14012

    Maximum measured plasma concentration at steady-state

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  8. Arm D, AUCτ,ss of DWP14012

    Area under the plasma concentration-time curve

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 11,(0 hours (pre-dose), 0.5~48 hours)

  9. Arm E, Cmax,ss of Meloxicam

    Maximum measured plasma concentration at steady-state

    Time frame: Day 7,(0 hours (pre-dose), 1~72 hours) / Day 16,(0 hours (pre-dose), 1~72 hours)

  10. Arm E, AUCτ,ss of Meloxicam

    Area under the plasma concentration-time curve

    Time frame: Day 7,(0 hours (pre-dose), 1~72 hours) / Day 16,(0 hours (pre-dose), 1~72 hours)

  11. Arm D, Cmax,ss of DWP14012

    Maximum measured plasma concentration at steady-state

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 13,(0 hours (pre-dose), 0.5~48 hours)

  12. Arm D, AUCτ,ss of DWP14012

    Area under the plasma concentration-time curve

    Time frame: Day 5,(0 hours (pre-dose), 0.5~48 hours) / Day 13,(0 hours (pre-dose), 0.5~48 hours)

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
    Recruiting
    • In-Jin Jang, MD, Ph.D · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Aug 2020, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Jul 29, 2020
StartActual
Jun 19, 2020
Primary completionEst.
Aug 31, 2020
CompletionEst.
Nov 30, 2020
Last update
Jul 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04490434
Responsible party
Sponsor
First posted
Jul 29, 2020
Start date
Jun 19, 2020
Primary completion
Aug 31, 2020 (estimated)
Completion
Nov 30, 2020 (estimated)
Last update
Jul 29, 2020

Study contacts

Jang In-Jin, MD, PhD
Contact
ijjang@snu.ac.kr
+82-2-2072-1910
Jang In-Jin, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion